Acadian Asset Management
UBX

Acadian Asset Management’s Unity Biotechnology UBX Stock Holding History

Acadian Asset Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,667
Closed -$11K – 1915
2023
Q1 		$11K Sell
7,667
-97,021
-93% -$389K ﹤0.01% 1684
2022
Q4 		$285K Buy
104,688
+55,892
+115% +$162K ﹤0.01% 1198
2022
Q3 		$191K Buy
48,796
+3,368
+7% +$21.2K ﹤0.01% 1223
2022
Q2 		$256K Buy
45,428
+6,439
+17% +$53.7K ﹤0.01% 1136
2022
Q1 		$435K Buy
38,989
+11,109
+40% +$125K ﹤0.01% 1036
2021
Q4 		$405K Buy
+27,880
New +$609K ﹤0.01% 1060

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Acadian Asset Management's UBX Position: Q2 2023 in Review

Acadian Asset Management sold out of Unity Biotechnology (UBX) in Q2 2023, closing a stake of 7,667 shares — an estimated $11K sold.

Acadian Asset Management first reported a position in UBX in Q4 2021 and held it in 6 quarters. The position peaked at $435K in Q1 2022. 40 funds tracked by Wall St. Rank hold UBX as of Q2 2023.

  • Acadian Asset Management reported no remaining Unity Biotechnology position as of Q2 2023 after selling out during the quarter.
  • Acadian Asset Management sold 7,667 Unity Biotechnology shares in Q2 2023, an estimated $11K.
  • Acadian Asset Management first reported a position in Unity Biotechnology in Q4 2021 and held it in 6 quarters.
  • Acadian Asset Management's Unity Biotechnology position peaked at $435K in Q1 2022.
  • 40 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2023.

Based on Acadian Asset Management's 13F filing for Q2 2023, filed 7 Aug 2023.